

AKIMA-DTSV 07 APR 2005

1103326-0527-Con

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Berg et al.
Serial No. : 10/807,918
Filing/371(c) Date : March 24, 2004
For : SUBSTITUTED INDAN DERIVATIVES
Examiner : Emily B. Bernhardt
Group Art Unit : 1624

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8 I hereby certify that this paper is being facsimile-transmitted to the U.S. Patent and Trademark Office on the date indicated below at the facsimile number 1-703-746-9195.	
Andrew Fessak	48,528
Name of Sender	PTO Reg. No.
<i>Andrew Fessak</i>	<i>4/6/05</i>
Signature	Date of Signature

REQUEST FOR CORRECTED FILING RECEIPT

Facsimile No:	1-703-746-9195	Office of Initial Patent Examination
Date:	April 6, 2005	Commissioner for Patents
Pages:	5 pages total	P.O. Box 1450
		Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

I. Attached is a copy of the official Filing Receipt received from the PTO in the above-referenced application for which issuance of a corrected Filing Receipt is respectfully requested.

II. There is an error on the Filing Receipt with respect to the following data, which is incorrectly entered and/or omitted.

Serial No. 10/807,918, filed March 24, 2004

Docket No. 1103326-0527-Con

Page 2 of 2

Error in

Correct data

- | | |
|----------------------------|--|
| 1. Applicant's name | 1. |
| 2. Applicant's address | 2. |
| 3. Title | 3. Title should read "Substituted Indian Derivatives" |
| 4. Filing Date | 4. |
| 5. Serial Number | 5. |
| 6. Foreign/PCT Application | 6. |
| 7. Continuing Data | 7. |
| 8. Power of Attorney | 8. |

A marked-up copy of the Filing Receipt is enclosed. Also enclosed is a copy of the first page of the application that shows the correct data.

- III. ☒ The correction(s) is/are not due to any error by Applicants and no fee is due.
☐ The requested correction is due to Applicants' error.

- IV. Issuance of a corrected Filing Receipt is respectfully requested.

Any fee which may be due in connection with this communication should be charged to Deposit Account 23-1703.

Dated: April 6, 2005

Respectfully submitted,

Andrew Fessak

Andrew Fessak

Reg. No. 48,528

Customer No. 007470

White & Case LLP

Agent's Direct Dial: (212) 819-8437

Enclosures: Marked-up copy of Filing Receipt (1 page)
Copy of first page of appln. (1 page)



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22311-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/807,918	03/24/2004	1614	1430	1103326-0527 CON	1	22	1

007470
WHITE & CASE LLP
PATENT DEPARTMENT
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

WHITE & CASE LLP CONFIRMATION NO. 3973
PATENT DEPARTMENT UPDATED FILING RECEIPT

JAN 31 2005



0C000000015007014

RECEIVED

Date Mailed: 01/24/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stefan Berg, Ekero, SWEDEN;
Lennart Florvall, Sodertalje, SWEDEN;
Svante Ross, Sodertalje, SWEDEN;
Seth-Olov Thorberg, Strangnas, SWEDEN;

Power of Attorney:

Nels Lippert-25888
Richard Kelly-27757
Robert Smith-28538
Dimitrios Drivas-32218
Cecilia Lofters-33434

John Scheibeler-35346
Richard Sterner-35372
David Bender-35445
Hans-Peter Hoffmann-37352
Scott Weingaertner-37756

Domestic Priority data as claimed by applicant

This application is a CON of 10/339,477 01/09/2003 ABN
which is a DIV of 09/171,575 10/21/1998 PAT 6,548,498
which is a 371 of PCT/SE98/01605 09/09/1998

Foreign Applications

SWEDEN 9703379-9 09/18/1997

If Required, Foreign Filing License Granted: 06/04/2004

The country code and number of your priority application, to be used for filing abroad under the Paris

Convention, is **US10/807,918**

Projected Publication Date: 05/05/2005

Non-Publication Request: No

Early Publication Request: No

Title

Substituted  Indian Derivatives

*should read
"Indan"*

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SUBSTITUTED INDAN DERIVATIVES

Field of the Invention

- The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives
- 5 as (*R*)- enantiomers, (*S*)-enantiomers or racemates in the form of free base or pharmaceutically acceptable salts or solvates thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.
- 10 An object of the invention is to provide compounds for therapeutic use, especially compounds having a selective effect at a subgroup of 5-hydroxytryptamine receptors, designated the h5-HT_{1B}-receptor (previously called the 5-HT_{1D β} -receptor) in mammals including man.
- 15 It is also an object of the invention to provide compounds with a therapeutic effect after oral administration.

Background of the Invention

- Various central nervous system disorders such as depression, anxiety, etc. appear to
- 20 involve the disturbance of the neurotransmitters noradrenaline (NA) and 5-hydroxytryptamine (5-HT), the latter also known as serotonin. The drugs most frequently used in the treatment of depression are believed to act by improving the neurotransmission of either or both of these physiological agonists. It appears that the enhancement of 5-HT neurotransmission primarily affects the depressed mood and anxiety, whereas the
- 25 enhancement of noradrenaline neurotransmission affects the retardation symptoms occurring in depressed patients. The invention concerns compounds which have an effect on 5-HT neurotransmission.

- Serotonin, or 5-HT, activity is believed to be involved in many different types of
- 30 psychiatric disorders. For instance it is believed that an increase in 5-HT activity is

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.